Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMARCA4 knockout CART19
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SMARCA4 knockout CART19 is an experimental CD19-directed chimeric antigen receptor T cell (CART19) product in which the SMARCA4 gene, a core ATPase subunit of the SWI/SNF chromatin-remodeling complex, has been genetically deleted in the CAR T cells to enhance their antitumor function. Preclinical work has shown that SMARCA4-deficient CART19 cells display increased cytotoxicity against CD19-positive targets and higher interferon-γ production compared with conventional CART19, suggesting that SMARCA4 loss reprograms T cell chromatin to favor effector differentiation and activity.[3][7] This next‑generation “armored” CAR T approach is being investigated at the research stage as a strategy to improve outcomes of CD19 CAR T therapies for B cell malignancies.
- Other names
- SMARCA4 KO CART19SMARCA-4 KO CART19SMARCA 4 KO CART19SMARCA4-deleted CART19SMARCA-4-deleted CART19SMARCA 4-deleted CART19SMARCA4 deletion CART19SMARCA-4 deletion CART19SMARCA 4 deletion CART19
02
Targets
SMARCA4 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on SMARCA4 knockout CART19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMARCA4 knockout CART19.